Revision History

1 revisions for "The FDA Opened the Door to an Experimental Pancreatic Cancer Drug. Who Gets to Walk Through It?"

The FDA granted expanded access to daraxonrasib, a RAS inhibitor made by Revolution Medicines that nearly doubled median survival in previously treated metastatic pancreatic cancer patients in the Phase 3 RASolute 302 trial. While the drug addresses a disease that kills roughly 50,000 Americans a year and has long resisted targeted therapy, questions about cost, equity, confirmatory trial requirements, and historical failure rates for early-access oncology drugs complicate the picture.